Mr. Rob Hutchison reports

BIOASIS ENTERS INTO A LICENSE AGREEMENT WITH VACCINEX INC.

Bioasis Technologies Inc. has entered into a licence agreement with Vaccinex Inc. Under the terms of the agreement, Vaccinex will have the right to commercialize its anti-semaphorin 4D antibody technology in combination with the Bioasis Transcend technology. The Vaccinex anti-sema4D technology targets neurodegenerative diseases, such as Huntington's disease and multiple sclerosis, the two initial neurology disease indications being investigated by Vaccinex. Currently the global market for Huntington's disease, as reported by GlobalData, was $252.6-million in 2014 with a projected growth to over $2.6-billion in 2024 (compound annual growth rate of 25.6 per cent). For multiple sclerosis, GlobalData reports that the global market was $17.2-billion in 2014 and projected to grow to $20-billion by 2024 (CAGR: 1.5 per cent) (1). Under the terms of the agreement, Vaccinex has been provided rights to the Transcend technology and its intellectual (patent) property, and upon achievement of specific events, Bioasis could receive up to $20-million (U.S.) in the form of upfront and milestone payments, and annual single-digit royalty payments upon commercialization.

Rob Hutchison, Bioasis chief executive officer, stated: "Facilitating the delivery of monoclonal antibodies across the blood-brain barrier to reach their therapeutic targets in the brain is the core focus of Bioasis. The combination of the Transcend technology and Vaccinex's unique anti-sema4D antibody has the potential to facilitate antibody delivery to the brain in patients suffering from neurological disorders, such as Huntington's disease and multiple sclerosis. We are looking forward to working with Vaccinex over the months and years to come."

Dr. Maurice Zauderer, Vaccinex chief executive officer, commented: "We are very pleased to be entering into this agreement and to collaborate with Bioasis. Their promising Transcend technology has unique potential to increase the efficiency of antibody delivery to multiple regions of the brain."

(1) See GlobalData website.

About Transcend

Transcend is Bioasis's proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for Bioasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About Bioasis

Bioasis Technologies is a biopharmaceutical company headquartered in the Vancouver, Canada, area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders.

We seek Safe Harbor.